Form 4: Cytek Biosciences' Chief Legal Officer Reports Stock Transactions

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On March 10, 2025, Valerie Barnett, the Chief Legal Officer of Cytek Biosciences, engaged in transactions involving the company's stock.
• Barnett exercised restricted stock units (RSUs), converting them into common stock.
• Specifically, 4,908 and 10,313 RSUs vested and were converted to common stock.
• Following the vesting, a portion of the shares (1,912 and 4,017 respectively) were withheld by Cytek Biosciences to cover tax obligations at a price of $4.36 per share.
• After these transactions, Barnett directly owns 73,372 shares of Cytek Biosciences common stock and 92,823 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of stock transactions related to executive compensation.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Companies like Bio-Rad Laboratories and Agilent Technologies also have similar filings when their executives exercise stock options or RSUs.
• The vesting schedules and tax withholding practices are generally consistent with industry norms for executive compensation.

Stakeholder Impact

• Shareholders are informed about insider transactions, promoting transparency.
• The transactions have a minor impact on the company's outstanding shares.

Key Dates